INTCO MEDICAL(SZ:300677) Sou Hu Cai Jing·2025-07-29 17:55Core Viewpoint - The financial performance of Yingke Medical shows significant growth in revenue and net profit, indicating a positive trend in the company's operations and market position [1]. Financial Performance - As of the first quarter of 2025, Yingke Medical reported total revenue of 2.494 billion yuan, representing a year-on-year increase of 13.20% [1]. - The net profit attributable to shareholders reached 353 million yuan, marking a year-on-year growth of 48.08% [1]. - The company's non-recurring net profit was 247 million yuan, with a year-on-year increase of 53.22% [1]. - The current ratio is 1.432, and the quick ratio is 1.357, indicating a healthy liquidity position [1]. - The debt-to-asset ratio stands at 51.61%, reflecting the company's leverage [1]. Stock Performance - As of July 29, 2025, Yingke Medical's stock closed at 32.19 yuan, with a slight decline of 0.03% [1]. - The trading volume was 204,200 hands, with a total transaction amount of 656.7 million yuan [1]. - The net outflow of main funds was 46.72 million yuan, accounting for 7.11% of the transaction amount [1]. Company Background - Yingke Medical Technology Co., Ltd. was established in 2009 and is located in Zibo City, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6.508 billion yuan and a paid-in capital of 635 million yuan [1]. - The legal representative of the company is Liu Fangyi [1]. Investment and Intellectual Property - Yingke Medical has made investments in 30 companies and participated in 54 bidding projects [2]. - The company holds 125 trademark registrations and 53 patents, along with 26 administrative licenses [2].